Antonio Frassoldati

6.4k total citations
156 papers, 2.8k citations indexed

About

Antonio Frassoldati is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Antonio Frassoldati has authored 156 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Antonio Frassoldati's work include Breast Cancer Treatment Studies (45 papers), HER2/EGFR in Cancer Research (44 papers) and Advanced Breast Cancer Therapies (35 papers). Antonio Frassoldati is often cited by papers focused on Breast Cancer Treatment Studies (45 papers), HER2/EGFR in Cancer Research (44 papers) and Advanced Breast Cancer Therapies (35 papers). Antonio Frassoldati collaborates with scholars based in Italy, United States and Spain. Antonio Frassoldati's co-authors include Pierfranco Conté, Valentina Guarneri, Giancarlo Bisagni, Federico Piacentini, Massimo Federico, Maria Vittoria Dieci, H.P. Sleeboom, Outi Paija, Antonio Llombart‐Cussac and Patrick Neven and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Antonio Frassoldati

151 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Frassoldati Italy	27	1.7k	876	705	689	481	156	2.8k
Giancarlo Bisagni Italy	25	1.9k 1.1×	747 0.9×	570 0.8×	832 1.2×	918 1.9×	127	2.9k
Marta Salido Spain	27	1.3k 0.7×	683 0.8×	709 1.0×	758 1.1×	177 0.4×	111	2.5k
Wael A. Harb United States	23	1.4k 0.8×	423 0.5×	923 1.3×	759 1.1×	273 0.6×	118	2.5k
José Á. García-Sáenz Spain	29	2.1k 1.2×	1.0k 1.1×	631 0.9×	1.0k 1.5×	316 0.7×	162	3.0k
Lorenzo Gianni Italy	21	1.2k 0.7×	600 0.7×	405 0.6×	526 0.8×	298 0.6×	91	2.0k
Valentina Boni Spain	29	2.3k 1.3×	771 0.9×	1.0k 1.4×	772 1.1×	771 1.6×	189	3.4k
Naoki Niikura Japan	26	1.7k 1.0×	918 1.0×	330 0.5×	902 1.3×	511 1.1×	147	2.5k
Morten Mau‐Sørensen Denmark	28	1.2k 0.7×	541 0.6×	1.1k 1.6×	527 0.8×	187 0.4×	130	2.7k
Alison M. Schram United States	25	1.1k 0.6×	783 0.9×	1.1k 1.5×	862 1.3×	139 0.3×	100	2.9k
Yaroslav Shparyk United States	24	3.0k 1.7×	965 1.1×	870 1.2×	2.4k 3.4×	234 0.5×	70	3.9k

Countries citing papers authored by Antonio Frassoldati

Since Specialization

Citations

This map shows the geographic impact of Antonio Frassoldati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Frassoldati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Frassoldati more than expected).

Fields of papers citing papers by Antonio Frassoldati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Frassoldati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Frassoldati. The network helps show where Antonio Frassoldati may publish in the future.

Co-authorship network of co-authors of Antonio Frassoldati

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Frassoldati. A scholar is included among the top collaborators of Antonio Frassoldati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Frassoldati. Antonio Frassoldati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moscetti, Luca, Isabella Sperduti, Elena Barbieri, et al.. (2024). Abstract PO1-05-02: CDK4/6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4/6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro/prospective observational study. Cancer Research. 84(9_Supplement). PO1–5. 1 indexed citations

Dieci, Maria Vittoria, Pierfranco Conté, Giancarlo Bisagni, et al.. (2023). Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer. JNCI Journal of the National Cancer Institute. 116(1). 69–80. 2 indexed citations

Muscaritoli, Maurizio, Alessandra Modena, Paolo Marchetti, et al.. (2023). The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study. Cancers. 15(12). 3206–3206. 9 indexed citations

Urso, Luca, Corrado Cittanti, Licia Uccelli, et al.. (2022). 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?. Clinical and Translational Imaging. 10(6). 687–695. 10 indexed citations

Urso, Luca, Angelo Castello, Stefano Panareo, et al.. (2022). Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. Journal of Cancer Research and Clinical Oncology. 148(6). 1299–1311. 38 indexed citations

Andrini, Elisa, Giuseppe Lamberti, Francesca Mazzoni, et al.. (2022). A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and Rationale. Future Oncology. 18(7). 771–779. 6 indexed citations

Urso, Luca, Alberto Nieri, Giorgia Valpiani, et al.. (2021). Clinical-Diagnostic Relevance of Breast “Incidentaloma” Detected During 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography. Indian Journal of Nuclear Medicine. 36(4). 385–390. 6 indexed citations

Griguolo, Gaia, Maria Vittoria Dieci, Laia Paré, et al.. (2021). Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. npj Breast Cancer. 7(1). 12–12. 15 indexed citations

Guarneri, Valentina, Maria Vittoria Dieci, Gaia Griguolo, et al.. (2021). Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European Journal of Cancer. 153. 133–141. 26 indexed citations

10.

Gori, Stefania, Fabio Puglisi, Michela Cinquini, et al.. (2018). Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). European Journal of Cancer. 99. 9–19. 10 indexed citations

11.

Ros, Lucia Da, Patrizia Querzoli, Massimo Pedriali, et al.. (2018). HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights. Clinical Breast Cancer. 18(5). e1133–e1139. 10 indexed citations

12.

Dieci, Maria Vittoria, Antonio Frassoldati, Daniele Generali, et al.. (2017). Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials. Breast Cancer Research and Treatment. 163(2). 295–302. 20 indexed citations

13.

Musolino, Antonino, Fabio Falcini, Daniela Boggiani, et al.. (2017). Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. European Journal of Cancer. 88. 10–20. 3 indexed citations

14.

Guarneri, Valentina, Maria Vittoria Dieci, Antonio Frassoldati, et al.. (2015). Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist. 20(9). 1001–1010. 67 indexed citations

15.

Arpino, Grazia, Daniele Generali, Anna Sapino, et al.. (2013). Gene expression profiling in breast cancer: A clinical perspective. The Breast. 22(2). 109–120. 57 indexed citations

16.

Giuliani, Jacopo, et al.. (2012). The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.. PubMed. 98(4). 408–12. 7 indexed citations

17.

Grisendi, Giulia, Rita Bussolari, István Peták, et al.. (2010). Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy. Cancer Research. 70(9). 3718–3729. 198 indexed citations

18.

Guarneri, Valentina, Antonio Frassoldati, Paolo Bruzzi, et al.. (2008). Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278). Clinical Breast Cancer. 8(5). 453–456. 40 indexed citations

19.

Guarneri, Valentina, Antonio Frassoldati, Federico Piacentini, et al.. (2008). Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial). Clinical Breast Cancer. 8(2). 192–194. 22 indexed citations

20.

Frassoldati, Antonio, Federico Piacentini, Roberto Sabbatini, et al.. (2005). IMPROVED SURVIVAL AFTER RADIOTHERAPY FOR BRAIN METASTASES IN PATIENTS WITH HER2 POSITIVE BREAST TUMORS. Breast Cancer Research and Treatment. 94. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact